Life Sciences IP Focus 2012

  • Editorial

  • Interview: Robert Armitage, Eli Lilly

    The American Invents Act could have a big effect on the life sciences industry. Kevin Matha spoke with Robert A Armitage, senior vice president and general counsel at Eli Lilly, about the new legislative package

  • Interview: Looking back on decades of industry change

    Tom Ciotti and Kate Murashige of Morrison & Foerster have been involved with the life sciences industry for almost 50 years. Phillip Bausk spoke with them about the changes they have seen in that time

  • Europe: Patenting plant breeding

    Edward J Farrington of Inspicos considers the role of human intervention when acertaining the limits of patentability in plant breeding

  • Europe: Selection inventions

    Louise Tottie and Anette Romare of Valea outline important aspects of selection inventions relating to lists and ranges, to consider when drafting patent applications

  • Mexico: New practice on medical-use claims

    Agustín Azcatl, Daniel Sánchez and Pedro Herrera of Olivares & Cia explain the impact of rule changes on first medical-use claims

  • US: The America Invents Act

    Ha Kung Wong and John Kirkland of Fitzpatrick Cella Harper & Scinto use three scenarios to examine the impact of the Act and the future of paragraph IV litigation


profile

Managing IP

ManagingIP

ManagingIP profile

Had a good planning call for our 10th Sept webinar on early dispute resolution today. More details & register here http://t.co/gh3Ka8t9q1

Sep 2 2014 05:23 ·  reply ·  retweet ·  favourite
ManagingIP profile

Due tomorrow from #CJEU: Deckmyn v Vandersteen judgment on copyright & parody http://t.co/ndAIMQwBPQ Any predictions from twitter?

Sep 2 2014 03:53 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @saji: . @ManagingIP The #PTAB is the biggest #patent development in years. Particularly from the validity perspective

Sep 2 2014 03:29 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


September 2014

The surprising rise of the PTAB

Patent owners have been shocked at how popular IPR proceedings at the PTAB have proven. As the USPTO mulls over changes and the Federal Circuit braces itself for a deluge of appeals, Michael Loney reports on how the PTAB is likely to evolve



Most read articles

Supplements